Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 2 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
1(50.0%)
Phase 1
1(50.0%)
2Total
Phase 2(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2)

Showing 2 of 2 trials
NCT06799741Phase 2Completed

A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection

Role: lead

NCT04273217Phase 1Completed

A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers

Role: lead

All 2 trials loaded